SELLAS Life Sciences (SLS) news
Recent news
3D Medicines Inc - arbitration proceedings against Sellas Life Sciences Group
3D Medicines Inc. has initiated arbitration proceedings against Sellas Life Sciences Group, citing alleged breaches of their licensing agreement. The dispute centers on the terms of a 2021 collaboration involving the development of targeted cancer therapies. 3D Medicines alleges that Sellas has…
AInvest Wire · Jul 27, 2026Sellas Life Sciences Group Inc: Maxim Group raises target price to $30 from $10
Maxim Group analyst Jason McCarthy has maintained a Buy rating on SELLAS Life Sciences Group (SLS) and raised the price target to $7.00 from $5.75, reflecting a more optimistic outlook for the stock. The company’s shares closed at $1.90 as of the latest trading session, significantly below the new…
AInvest Wire · Jul 8, 2026Sellas Life Sciences shares jump 23% after 1Q results
AInvest Wire · May 12, 2026WH budget calls for ending Boeing SLS after 3 flights, demands major cuts to NASA science
AInvest Wire · May 2, 2025ImportantSellas Life Phase 3 trial hits 60 deaths, IDMC analysts triggered
Sellas Life Phase 3 trial hits 60 deaths, IDMC analysts triggered The ongoing Phase 3 trial of Sellas Life Sciences' galinpepimut-S (GPS) in acute myeloid leukemia (AML) has received a positive recommendation from the Independent Data Monitoring Committee (IDMC) [1]. This recommendation comes after…
AInvest Wire · Dec 10, 2024Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.